Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer by Paola Zagami, Angela Esposito, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Roberta Scafetta, Matteo Lambertini, Massimo Di Maio, Giuseppe Curigliano, Carmen Criscitiello, Saverio Cinieri

“…Purpose: CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be influenced by adverse events (AEs). …”
Get full text

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer by Jorge L. Soriano, Noyde Batista, Eduardo Santiesteban, Mayté Lima, Joaquín González, Robin García, Yohanka Zarza, María V. López, Myriam Rodríguez, Jorge L. Loys, Narciso Montejo, Frank Aguirre, Amparo Macías, Ana M. Vázquez

“…The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. …”
Get full text

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context by Niels A.D. Guchelaar, Ron H.J. Mathijssen, Maaike de Boer, Marlies L. van Bekkum, Joan B. Heijns, Birgit E.P.J. Vriens, Mandy M. van Rosmalen, Lonneke W. Kessels, Lisanne Hamming, Karin J. Beelen, Peter Nieboer, Susan M. van den Berg, Esther Oomen-de Hoop, Rhodé M. Bijlsma, Monique E.M.M. Bos

Subjects: Get full text

Lipid‐coated bismuth nanoflower as the thermos‐radio sensiti for therapy of lung metastatic breast cancer: Preparation, optimisation, and characterisation by Shushu Xue, Junrong Jiao, Si Miao, Lijun Wang, Yang Liu, Qingjie Zhang, Qiyue Wang, Yu Xi, Yuanyuan Zhang

Subjects: Get full text

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy by Gabriel Tremblay, Unnati Majethia, Ilias Kontoudis, Jesús De Rosendo

“…**Background:** Two thirds (62%) of metastatic breast cancer (MBC) patients in Western Europe have human epidermal growth factor receptor 2 (HER2)-negative disease, for which anthracyclines and taxanes are recommended as first-line treatments, followed by microtubule-targeting agents such as capecitabine, vinorelbine and/or eribulin. …”
Get full text

Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study by Seyed Mohamad Sadegh Mousavi-kiasary, Mahdis Bayat, Fereshteh Abbasvandi, Batoul Khoundabi, Fatemeh Mousavi, Atieh Akbari, Maryam Bagherian, Afsoon Zandi, Behnam Honarvar, Mohammad Esmaeil Akbari

Get full text

Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study by Yan Chen, Yu Qiu, Haoyang Shen, Shuixin Yan, Jiadi Li, Weizhu Wu

“…Abstract Background This study aimed to construct, evaluate, and validate nomograms for breast cancer-specific survival (BCSS) and overall survival (OS) prediction in patients with HER2- overexpressing (HER2+) metastatic breast cancer (MBC). Methods The Surveillance, Epidemiology, and End Results (SEER) database was used to select female patients diagnosed with HER2 + MBC between 2010 and 2015. …”
Get full text

Personal and behavioural factors that influence physical activity in women living with metastatic breast cancer: a qualitative interview study by Mark Liu, Sharon Kilbreath, Jasmine Yee, Jane Beith, Justin McNab, Elizabeth Dylke

“…Abstract Background Women living with metastatic breast cancer can benefit from physical activity. …”
Get full text

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer by Elizabeth J. Anderson, Lea E. Mollon, Joni L. Dean, Terri L. Warholak, Ayal Aizer, Emma A. Platt, Derek H. Tang, Lisa E. Davis

Get full text

Discovery of a sushi domain-containing protein 2-positive phenotype in circulating tumor cells of metastatic breast cancer patients by Kai Bartkowiak, Parinaz Mossahebi Mohammadi, Paula Nissen, Stefan Werner, David Agorku, Antje Andreas, Maria Geffken, Sven Peine, Karl Verpoort, Thomas M. Deutsch, Laura L. Michel, Andreas Schneeweiss, Verena Thewes, Andreas Trumpp, Olaf Hardt, Volkmar Müller, Sabine Riethdorf, Hartmut Schlüter, Klaus Pantel

“…Expression of SUSD2 on subsets of CTCs was validated on clinical blood samples of patients with metastatic breast cancer. SUSD2-positive CTCs could be captured specifically by a MACS-based approach. …”
Get full text

High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors by Atsushi Fushimi, Isao Tabei, Azusa Fuke, Tomoyoshi Okamoto, Hiroshi Takeyama

“…This retrospective analysis investigated the outcomes of 19 women with postmenopausal hormone-sensitive recurrent or metastatic breast cancer who received HD-TOR, defined as 120 mg daily from 2012 to 2016. …”
Get full text

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors by Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra

Subjects: “…metastatic breast cancer…”
Get full text

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study by Seda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, Deniz Can Guven, Ozge Gumusay, Basak Oyan Uluc, Ertugrul Bayram, Burcu Gulbagci, Alper Yasar, Sena Ece Davarci, Eda Eylemer Mocan, Omer Acar, Deniz Isik, Esra Aydin, Yusuf Karakas, Melike Ozcelik, Murat Keser, Sadi Kerem Okutur, Onder Eren, Serkan Menekse, Dincer Aydin, Funda Yilmaz, Ozlem Dogan, Gulhan Ozkanli, Hakan Yucel, Veli Sunar, Musa Baris Aykan, Ozlem Ozdemir, Berna Bozkurt Duman, Merve Keskinkilic, Teoman Sakalar, Ali Inal, Muge Karaoglanoglu, Asude Aksoy, Muhammed Muhiddin Er, Nazim Serdar Turhal, Nurhan Onal Kalkan, Mehmet Ali Nahit Sendur

Subjects: Get full text

Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study by Akif Doğan, Nurullah İlhan, Goncagül Akdağ, Sedat Yıldırım, Mustafa Seyyar, Zeynep Yüksel Yaşar, Hande Nur Erölmez, Heves Sürmeli, Buğra Öztosun, Özlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yıldırım, Devrim Çabuk, Nedim Turan, Mahmut Gümüş

Subjects: “…premenopausal metastatic breast cancer…”
Get full text

RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer by Zhe Rong, Li Li, Fei Fei, Lailong Luo, Yang Qu

Get full text

The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer by Ting Xu, Weili Xiong, Lili Zhang, Yuan Yuan

“…The study preliminarily demonstrates that anlotinib combined with chemotherapy may be an optional recommendation for patients with HR+/HER2– metastatic breast cancer who have progressed after CDK4/6i.…”
Get full text

Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study by François-Clément Bidard, Lisa Belin, Suzette Delaloge, Florence Lerebours, Charlotte Ngo, Fabien Reyal, Séverine Alran, Sylvie Giacchetti, Michel Marty, Ronald Lebofsky, Jean-Yves Pierga

“…Introduction. In non-metastatic breast cancer patients, the REMAGUS02 neoadjuvant study was the first to report a significant impact of circulating tumor cells (CTCs) detection by the CellSearch system on the distant metastasis-free survival (DMFS) and overall survival (OS) endpoints. …”
Get full text

A patient-led survey on information and communication needs of patients with metastatic breast cancer in Ireland and Northern Ireland (CTRIAL-IE 23–05) by Siobhan Gaynor, Yvonne O'Meara, Emer Mulvaney, Rachel J. Keogh, Catherine S. Weadick, Fran J. Duane, Ann Mc Brien, Helen Greally, Mary Jane O'Leary, Ieva Teiserskyte, Isabel Beristain, Jacinta Marron, Eibhlin Mulroe, Vicky Donachie, Sarah Mc Loughlin, Seamus O'Reilly

“…Introduction: Although treatment advances have improved survival rates for patients with metastatic breast cancer (MBC), patient expressed needs have not been evaluated in Ireland to date. …”
Get full text

Retraction Note: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer by Zhe Rong, Li Li, Fei Fei, Lailong Luo, Yang Qu

Get full text

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them by L. Foffano, L. Cucciniello, E. Nicolò, I. Migliaccio, C. Noto, C. Reduzzi, L. Malorni, M. Cristofanilli, L. Gerratana, F. Puglisi

Subjects: “…Metastatic breast cancer…”
Get full text